Clinical trials · Maryland
Chronic Hepatitis B clinical trials in Maryland
We’re tracking 16 recruiting chronic hepatitis b studies with a site in Maryland — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT07654283RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Baltimore, MarylandAges 18–65 - NCT06092333RecruitingPhase 2
New combo therapy for chronic hepatitis B
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
Bethesda, MarylandAges 18–65 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Baltimore, MarylandAges 18 years+ - NCT04588077RecruitingPhase 4
Two-dose vs three-dose hepatitis B vaccine for cirrhosis
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
Baltimore, MarylandAges 18 years+ - NCT04843852RecruitingPhase 1
Test vaccine added to hepatitis B treatment
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Baltimore, MarylandAges 18 years+ - NCT06154278RecruitingPhase 2
Testing imdusiran for chronic hepatitis B
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Baltimore, MarylandAges 18 years+ - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT07096193RecruitingPhase 1/Phase 2
Study of GS-4321 for chronic hepatitis delta
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
Baltimore, MarylandAges 18–69 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bethesda, MarylandAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Bethesda, MarylandAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Baltimore, MarylandAges 18 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Baltimore, MarylandAges 18 years+ - NCT05254743RecruitingPhase 3
Pirtobrutinib versus ibrutinib for CLL or SLL
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
Bethesda, MarylandAges 18 years+ - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT07113743Enrolling by invitationPhase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
Bethesda, MarylandAges 3–60
Chronic Hepatitis B trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting chronic hepatitis b studies listed above.
- National Institutes of Health Clinical Center · 4 studies
- University of Maryland, Baltimore · 3 studies
- University of Maryland · 2 studies
- Akero Clinical Study Site
- American Oncology Partners, PA
- Grifols Investigative Site
- Mercy Medical Center
- The Center for Cancer and Blood Disorders
What taking part in a chronic hepatitis b study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there chronic hepatitis b clinical trials in Maryland?
- Yes. We're currently tracking 16 recruiting chronic hepatitis b studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic hepatitis b study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic hepatitis b trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic hepatitis b studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.